The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States
2008

The Cost of Pharmaceutical Promotion in the US

Sample size: 2000 publication Evidence: high

Author Information

Author(s): Marc-André Gagnon, Joel Lexchin

Primary Institution: Université du Québec à Montréal, York University

Hypothesis

A new estimate of pharmaceutical promotion expenditures is needed to understand the industry's spending compared to research and development.

Conclusion

Pharmaceutical companies spend almost twice as much on promotion as they do on research and development.

Supporting Evidence

  • Pharmaceutical companies spent US$33.5 billion on promotion in 2004 according to CAM.
  • IMS reported US$27.7 billion for the same year.
  • The study found that promotion consumes 24.4% of sales compared to 13.4% for R&D.

Takeaway

Pharmaceutical companies spend a lot of money to promote their drugs, much more than they spend on research to make new ones.

Methodology

The study compared promotional spending estimates from IMS and CAM, using proprietary databases and surveys of physicians.

Potential Biases

Companies may underestimate promotional costs to enhance their public image.

Limitations

The estimates may be incomplete due to unmonitored promotional spending and reliance on self-reported data from companies.

Participant Demographics

The study surveyed a representative sample of 2,000 primary care physicians and 4,800 specialists in the US.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0050001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication